Russian tirzepatide became the first on the market of Kazakhstan

08.09.2026

Corporate
Medicines
Industry development
International focus
The Russian pharmaceutical company Promomed has received a registration certificate from the Ministry of Health of Kazakhstan for the drug Tirzetta (active ingredient — tirzepatide), used for the treatment of type 2 diabetes and obesity. The supply of medicines to the republic will begin in the near future.

"Tirzetta" will be the first drug with this active ingredient officially available on the market of Kazakhstan. According to the state the registry According to the Ministry of Medicines of the Republic, not only alternative generics, but also the original Mounjaro drug from the American Eli Lilly have not yet been registered in the country. data The Ministry of Health of Kazakhstan, the original remedy is currently undergoing the registration procedure.

Promomed is counting on high demand. According to the World Health Organization for 2024, 56% of adult residents of Kazakhstan are overweight, which exceeds the global average (45%).

In Russia, drugs based on tirzepatide — "Tirzetta" from Promomed and "Sejaro" from Geropharm — became sales leaders in the commercial segment by mid-2026. According to the DSM Group, in the first seven months of 2026, sales of these funds in Russian retail increased 21—fold in monetary terms, to 33.03 billion rubles. In physical terms, the market volume increased 27-fold, reaching 3.71 million packages.



Sources
  1. kommersant.ru

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office